Epogen, Procrit, Epoetin Alfa


Add to MyYahoo RSS

Epogen, Procrit, Epoetin Alfa News

News on Epogen, Procrit, Epoetin Alfa (generic) continually updated from thousands of sources around the net.

Wednesday Aug 6 | Hispanic Business

Dendreon Names W. Thomas Amick President and Chief Executive Officer

Most recently from 2010 to 2012, he served as chairman and chief executive officer of where, as vice president of the Ortho Biotech Oncology Franchise, he launched Procrit and built J&J's oncology franchise into a multi-billion dollar operation, making Procrit the most successful product in J&J history at the time.


Related Topix: Dendreon, Oncology, Medicine, Biotech, Science / Technology

Mon Aug 04, 2014

Business Journal

Express Scripts drops 25 more drugs from its formulary

Express Scripts has announced that it will remove 25 more treatments from its 2015 list of preferred drugs, including two anemia drugs sold by Amgen Inc. Epogen and Aranesp will not be included on the formulary, but Johnson & Johnson's anemia drug, Procrit, will still be covered, Reuters reports.


Related Topix: Biotech, Amgen, Medicine, Healthcare Industry

Fri Aug 01, 2014


UPDATE 1-Express Scripts drops Amgen anemia drugs from formulary

Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc. The company will continue to include Procrit, a similar anemia drug sold by Johnson & Johnson, on its list of preferred drugs, ... (more)


Related Topix: Biotech, Medicine, Amgen, Express Scripts, Healthcare Industry, Anemia, Health, Johnson and Johnson, Johnson and Johnson Merck Consumer Pharmaceuticals

Wed Jul 30, 2014

Pharmaceutical Processing

Dendreon Names New President and Chief Executive Officer

Dendreon Corporation announced that its board of directors has appointed W. Thomas Amick as president and chief executive officer, effective immediately.


Related Topix: Dendreon, Biotech, Medicine, Discovery Laboratories, Healthcare Industry, Science / Technology, Johnson & Johnson

Tue Jul 29, 2014

The Boulder County Business Report

Amgen shutting down Boulder, Longmont sites

Biologic drugmaker Amgen said Tuesday that it will lay off 12 percent to 15 percent of its worldwide workforce and close four sites, including those in Boulder and Longmont, even as it reported very strong second-quarter results that trounced Wall Street expectations.


Related Topix: Longmont, CO, Boulder, CO, Boulder County, CO, Medicine